SecProbe.io

CORRESP
1
filename1.htm

FIBROBIOLOGICS,
INC.

455
E. Medical Center Blvd.

Suite
300

Houston,
Texas 77598

June
21, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attention:
    Doris
    Stacey Gama

    RE:
    FibroBiologics,
    Inc. (the “Company”)

    Registration
    Statement on Form S-1

    File
    No. 333-280303

    Withdrawal
    of Acceleration Request

Dear
Mrs. Gama:

Reference
is made to our letter filed as correspondence with the Securities and Exchange Commission via EDGAR on June 18, 2024 (the “Acceleration
Request”), in which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form
S-1 (File No. 333-280303) (the “Registration Statement”), to 5:00 p.m. Washington D.C. time on June 21, 2024, or as soon
as practicable thereafter, pursuant to Rule 461(a) under the Securities Act of 1933, as amended. We are no longer requesting that the
Registration Statement be declared effective at such date and time and we hereby formally, and with immediate effect, withdraw our request
for acceleration of the effective date.

Please
direct any questions with respect to the withdrawal of the Acceleration Request of the Registration Statement
to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP.

    Very
    truly yours,

    FibroBiologics,
    Inc.

    By:
    /s/
    Mark Andersen

    Name:

    Mark
    Andersen

    Title:

    Chief
    Financial Officer